WinstonWınston
Back
Stock

Sanofi

SNY
64
Drug Manufacturers - General · Healthcare
Price
$40.61
+0.32 (+0.79%)
Market Cap
$97.31B
Exchange
NASDAQ
Winston Score
64
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Oct 18, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Good
18/30
Growth
Mixed
9/20
Cash Flow
Exceptional
9/10
Stability
Strong
8/10
Valuation
Strong
7/10
Ownership
Good
8/15
Dividends
Exceptional
5/5

64 of 100 counted points = Winston Score 64.

Track this stock — start free trial

Share count falling — buybacks

−2.6% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 2.50B (2021) → 2.44B (2025)

§Winston Score History

The full picture

Sanofi is a large French pharmaceutical company that makes prescription medicines, vaccines, and consumer health products. Its biggest products include Dupixent, a drug that treats eczema, asthma, and other inflammatory conditions, along with a broad portfolio of vaccines sold under its Sanofi Pasteur brand. The company sells to hospitals, pharmacies, doctors, and governments around the world.

Sanofi earns money primarily by selling branded drugs and vaccines, with Dupixent now generating tens of billions in annual sales and acting as the company's main growth engine. It operates globally, with strong presence in Europe, North America, and emerging markets, making it one of the largest pharmaceutical companies in the world by revenue. The key risk is that Sanofi is heavily dependent on Dupixent for growth, so any safety concerns, competition from biosimilars, or pricing pressure on that single drug could significantly hurt the business.

Politician Trades

1 trades / 12mo

1 Congressional buy and 0 sells on SNY in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+14.6% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-91.3% YoY

YoY Growth Rate

Earnings declining

R&D Spend

€7.8B/ year

↑ Rising (+6% vs prior year)

16.8% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

9.5%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

€6.3B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Sanofi is putting 17% of revenue into R&D and that number is rising. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
75.5%
Premium pricing power — 75.5% gross margin
Profit after running costs
Operating Margin
19.4%
Healthy — 19.4% operating margin
Return on the money invested
ROCE
8.0%
Weak — 8.0% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+13.4%
Fast-growing sales (+13.4% YoY)
Profit growth
EPS YoY
-87.5%
Earnings shrinking (-87.5% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
215%
Turns 215% of profit into real cash
Spare cash per sale
FCF Margin
17.8%
Converts sales into free cash efficiently (17.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.31
Conservative — low debt load (0.31)
Covers its interest
Interest Cover
12.24x
Comfortably covers interest (12.2x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
22.0x
Growth-priced — P/E 22.0

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year
P/E vs Forward
+14.4
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (22.0 → 7.6)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
5.69%
Healthy income — 5.69% yield

Generous yield. Worth checking whether the payout is sustainable.

Dividend record
Dividend Growth
+49.4%
Dividend growing fast (49.4% YoY)
Payout Ratio
124%
no trend
Paying out more than the last 12 months of profit. The dividend is being funded from cash or borrowing, not this year’s earnings.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial